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FoundationSee page 999Coronary artery disease, including acute myocardial infarc-
tion (AMI), is the leading cause of morbidity and mortality
in industrialized countries (1). Acute and chronic myocardial
ischemia leads to myocardial necrosis with up-regulation of
different markers of necrosis, cellular adhesion, remodeling,
systemic inﬂammation, and platelet activation (2–4). Someorax Center, Department of Cardiology, Bad
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, 2012; revised manuscript received April 17,of these markers are useful in diagnosing and treating
patients with acute coronary syndromes (5–8).Recent studies demonstrated that microRNAs (miRNAs)
are also up-regulated in patients with AMI, distinguishing
between patients with and without myocardial necrosis
(9–15). Especially elevated concentrations of miR-133a in
patients with ST-segment elevation myocardial infarction
(STEMI) are associated with larger myocardial infarcts,
reperfusion injury, and decreased myocardial salvage (13).
Therefore, these studies suggest that circulating miRNAs
might be useful as potential biomarkers for AMI; however,
it is challenging to establish this. Several studies have
demonstrated that animal models of AMI can provide
information about the release kinetics of miRNAs (10,11);
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993however, such ﬁndings cannot be directly extrapolated to
patients due to different physiological parameters (e.g.,
metabolism and release) (16–18).
Until now, there have been no data about the exact release
kinetics of cardiac-speciﬁc (miR-21, miR-208a) and muscle-
enriched (miR-1, miR-133a) miRNAs in patients with
AMI. Due to the inaccurate deﬁnition of the exact time point
of the beginning ofmyocardial ischemia and the patient-related
time delays before presentation to the hospital, the early release
kinetics of miRNAs have not yet been described. Thus, the
present study aimed to characterize the time-dependent in-
creases in cardiac-speciﬁc and muscle-enriched miRNAs in
patients undergoing transcoronary ablation of septal hyper-
trophy (TASH) as a model for patients with AMI.Table 1
Baseline Characteristics of the Study Patients
(N ¼ 21)
Age, yrs 59.0  13.3
Male 13 (61.9)
BMI, kg/m2 30.2  6.9
Cardiovascular risk factors
Current smoker 10 (47.6)
Hypertension 13 (61.9)
Hypercholesterolemia 6 (28.6)
Diabetes mellitus 6 (28.6)
Family history of coronary artery disease 6 (28.6)
Laboratory measurements
Creatinine, mmol/l 68.6 (66.9–81.8)
eGFR, ml/min/1.73 m2 90.5 (79.0–113.7)
CK-MB, mg/l 0.9 (0.4–1.1)
hs-cTnT, ng/l 11.3 (6.0–18.8)
Myoglobin, mg/l 38.0 (28.0–56.0)
Values are mean  SD, n (%), or median (interquartile range).
CK-MB ¼ creatine kinase-myocardial band; BMI ¼ body mass index; eGFR ¼ estimated
glomerular ﬁltration rate; hs-cTnT ¼ high-sensitivity cardiac troponin T; IQR ¼ interquartile range.Methods
Study design. From January 2010 until June 2011, 21
consecutive patients with hypertrophic obstructive cardio-
myopathy who were undergoing TASH were included in
the study. The pre- and post-procedural management of
these patients was recently published (19,20). In brief,
clinical history, physical examination, 12-lead electrocardi-
ography, laboratory tests, echocardiography, and coronary
angiography were assessed in all patients. The ﬁnal diag-
nosis of hypertrophic obstructive cardiomyopathy was made
according to the current guidelines, based on severe symp-
toms during physical activity, asymmetrical septal hyper-
trophy >15 mm, systolic movement of the anterior mitral
valve leaﬂet, and an intraventricular pressure gradient 30
mm Hg at rest and/or >50 mm Hg after provocation by the
Valsalva maneuver (21). TASH was performed according to
standard clinical practice, with temporary septal branch
occlusion for selective therapeutic injection of 96% ethanol.
Post-procedural management included monitoring at the
intensive care unit for 48 h. All patients provided written
informed consent for their participation in the study, and
approval of the ethics board (FF 31/2010) was obtained.
The investigation conformed to the principles outlined in
the Declaration of Helsinki.
Laboratory assessment. Venous blood samples for the
determination of cardiac-speciﬁc (miR-21, miR-208) and
muscle-enriched (miR-1,miR-133a)miRNAswere collected
before and at 15, 30, 45, 60, 75, 90, and 105 min and 2, 4, 8,
and 24 h after the induction of MI. Serum was processed
immediately and frozen at –80C until assayed.
The miRNAs were isolated from 400 ml of serum using
the miRNeasy Isolation Kit (Qiagen, Hagen, Germany).
After the addition of Qiazol (Qiagen), the samples were
spiked using 10-nM native cel-miR-39 (Life Technologies,
Darmstadt, Germany). For reverse transcription, the Taq-
Man miRNA Reverse Transcription Kit (Life Technolo-
gies) and the target-speciﬁc TaqMan-miRNA Gene
Expression Kit (Life Technologies) were used. Quantitative
real-time polymerase chain reaction was performed in an
ICycler (BioRad, Munich, Germany) in 20 ml of internalstandard containing 100-nM
primer, 1  TaqMan universal
Master Mix II, no UNG
(Life Technologies, Darmstadt,
Germany), and 1 ml of cDNA
(1:10). Assays were performed in
triplicate. The relative amount of
target miRNA was normalized to
cel-miR-39.
Statistical analysis. All data for
continuous variables are expressed
as mean  SD or as median (interquartile range [IQR]) when
appropriate. Categorical variables are reported as number (%).
Continuous variables were compared using the Wilcoxon
signed rank test. Within-subject comparisons are made across
repeated observations without correction for multiple com-
parisons. The data are distributed parametrically as tested by
the Kolmogorov-Smirnov test. Linear regression analysis was
performed to determine the relationships between cardiac
troponin T (cTnT) and the different miRNAs using the
logarithmic masses. This correlation integrated the concen-
tration over time for the ﬁrst 120 min after the initiated MI.
All statistical tests were performed with SPSS software
version 15.0 (Systat Software, Inc, Chicago, Illinois). A 2-
tailed p value of <0.05 was considered to be statistically
signiﬁcant.Results
The clinical characteristics of all of the patients (13 men,
8 women; mean age: 59.0  13.29 years) enrolled in the
study are shown in Table 1. The mean left ventricular
ejection fraction as measured by echocardiography was
61.5  6.38%. All TASH procedures were performed in
a single session using a single septal branch occlusion.
During the procedure, the mean amount of administered
Table 2 MiRNA Concentrations (N ¼ 21)
Time miR-1 miR-133a miR-21 miR-208a
Baseline 1.7 (1.1–2.0) 0.9 (0.5–1.8) 1.4 (0.9–1.9) ULD (ULD–0.8)
15 min 4.2 (1.7–8.3) 2.9 (2.0–5.0) 1.1 (0.8–2.2) ULD (ULD–0.7)
30 min 8.6 (1.9–23.8) 8.8 (2.1–15.3) 1.2 (0.7–1.6) 0.3 (ULD–0.9)
45 min 26.8 (7.5–64.4) 27.4 (6.6–75.9) 0.8 (0.4–1.8) ULD (ULD–1.3)
60 min 33.3 (5.6–68.3) 28.8 (5.2–66.8) 0.9 (0.7–1.6) 0.7 (ULD–1.9)
75 min 66.8 (35.1–115.7) 51.8 (13.5–85.6) 1.2 (0.9–1.9) 2.3 (0.9–3.1)
90 min 43.3 (11.9–171.6) 36.9 (12.1–148.4) 1.1 (0.5–1.8) 1.5 (ULD–3.5)
105 min 67.2 (24.9–152.6) 49.8 (28.1–186.9) 1.6 (0.9–2.1) 2.8 (ULD–4.3)
120 min 54.3 (7.5–150.9) 54.9 (9.1–123.1) 1.3 (0.9–2.2) 1.0 (0.2–2.6)
240 min 74.6 (15.1–194.3) 40.2 (20.3–294.4) 1.1 (0.2–1.9) 1.6 (0.7–2.8)
480 min 31.9 (5.6–156.6) 72.2 (8.1–179.5) 0.9 (0.4–1.8) 1.2 (0.2–2.9)
1,400 min 10.3 (3.3–45.2) 31.2 (5.9–67.7) 0.6 (0.4–3.0) 0.9 (0.4–1.9)
Values are median (interquartile range).
miR ¼ microRNA; ULD ¼ under lower limit of detection.
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20.0 min (IQR: 14.5 to 31.0 min).
The concentrations of miR-1, miR-21, miR-133a, and
miR-208a, according to the pre-speciﬁed time points, are
shown in Table 2. Measurements of circulating miR-1 serum
concentrations revealed a signiﬁcant increase at 15 min after
the induction of MI compared with baseline concentrations
(4.2 [IQR: 1.7 to 8.3] vs. 1.7 [IQR: 1.1 to 2.0]; p ¼ 0.01).
The miR-1 concentrations showed a continuous rise after 75
min (66.8 [IQR: 35.1 to 115.7]) compared with baseline
(p < 0.001) and a peak after 4 h (Fig. 1A).
Serum concentrations of miR-133a were also signiﬁcantly
increased at 15 min after the induction of MI compared with
baseline (2.9 [IQR: 2.0 to 5.0] vs. 0.9 [IQR: 0.5 to 1.8];
p < 0.01), with a peak at 75 min after TASH (51.8 [IQR:
13.5 to 85.6]) compared with baseline (p < 0.01). The miR-
133a concentrations were decreased between the 4th and
8th hour after TASH, reaching a 30-fold change after 24 h
compared with baseline values (Fig. 1B). All patients had
signiﬁcantly increased concentrations (more than 100%) of
miR-1 and miR-133a after 45 min (ranges of absolute
increase: miR-1, 2.2 to 112.1; miR-133a, 2.1 to 131.9).
Serum concentrations of miR-208a were signiﬁcantly
increased at 105 min after MI was initiated (2.8 [IQR:
undetectable to 4.3] vs. undetectable [IQR: undetectable to
0.8] at baseline; p < 0.01) (Table 2, Fig. 1C). There was no
further increase during the pre-speciﬁed time points. The
highest increase in miR-21 concentration was measured at
105 min after TASH (1.69 [IQR: 1.05 to 2.23] vs. 1.4
[IQR: 0.9 to 1.9] at baseline; p ¼ 0.06) (Fig. 1D).
The release kinetics of high-sensitivity (hs)-cTnT (Roche
hs-assay) in this patient cohort were recently published (19).
In brief, all patients had a signiﬁcant increase in hs-cTnT
concentrations of more than 50% at 15 min after the
induction of MI compared with baseline concentrations (21.4
ng/l [IQR: 13.3 to 39.7 ng/l] vs. 11.3 ng/l [IQR: 6.0 to 18.8
ng/l]; p ¼ 0.031) (range of percent increase: 171.4% to
257.5%; range of absolute increase: 3.71 to 38.7 ng/l). The
hs-cTnT concentrations showed a continuous rise at all pre-speciﬁed time points and measured above the 99th percentile
at 30 min post-procedure in all patients. In contrast, miR-1,
miR-133a, and miR-208a concentrations showed increases
during the ﬁrst 2 h after TASH and started to decrease
between the 4th and 8th hour after TASH.
Figure 2 shows the linear regression analysis of the rela-
tionships between the hs-cTnT measurements, representing
the extent of myocardial injury, and the different miRNAs
(using logarithmic masses) during the ﬁrst 120 min after the
induction of MI. Serum concentrations of miR-1 were pos-
itively correlated with the hs-cTnT (r2 ¼ 0.95; p < 0.001)
(Fig. 2A). Similar correlations were observed for miR-133a
(r2 ¼ 0.97; p < 0.001) (Fig. 2B). The serum concentra-
tions of miR-21 and miR-208a did not show any signiﬁcant
correlation with hs-cTnT (Figs. 2C and 2D). Additionally,
there were no sex-speciﬁc differences observed among the
rates of increase for the different miRNAs.
Discussion
Published data have illustrated the diagnostic and prognostic
effects of miRNAs in patients with AMI (9–15,22–29).
Furthermore, a recently published study reported on the
regulation of different circulating miRNAs during trans-
coronary passage in patients with acute coronary syndromes
(12). However, less is known about the exact release kinetics
of cardiac-speciﬁc and muscle-enriched miRNAs in patients
with AMI.
The present study is the ﬁrst to precisely describe the early
release of cardiac-speciﬁc and muscle-enriched miRNAs
after the induction of MI as a surrogate for AMI in a cohort
of patients undergoing TASH. In this study, the TASH
procedure was assumed to be a valuable model of AMI due
to its well-deﬁned chronological biomarker release after the
induction of ischemia (19,20). Although animal models of
AMI can provide information about the release kinetics of
miRNAs, these ﬁndings cannot be directly transferred to
humans because of the different physiological parameters
(10,15). In a murine model, muscle-derived miRNAs were
Figure 1 Median (IQR) Fold-Changes in Serum miRNA Concentrations in All Patients (N ¼ 21)
(A) miR-1; (B) miR-133a; (C) miR-208a; and (D) miR-21. *p < 0.05 versus baseline. IQR ¼ interquartile range; miR ¼ microRNA.
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995elevated within 1 h after the induction of coronary artery
ligation (10). In humans, circulating miR-1 and miR-133a
concentrations were elevated as early as 156 min after the
onset of symptoms and declined thereafter (10,11,22).
However, until now, the use of circulating miRNAs as
biomarkers for cardiovascular diseases in daily clinical prac-
tice was limited due to several factors and the lack of stan-
dardization of the measurements. miRNAs are stable in
serum, plasma, or whole blood, but RNA isolation and
subsequent quantiﬁcation by real-time polymerase chain
reaction are time consuming and difﬁcult to perform on
a regular basis in clinical practice (30). Either serum, plasma,
or whole blood is suitable for miRNA measurement, but
whole blood might be more consistent as the additional
variability of clotting is not required. In contrast, to avoid cell
lysis, which might affect miRNA concentrations, whole
blood samples should not be subjected to freeze–thaw cycles.
Plasma, serum, and whole blood concentrations of circulating
miRNAs may be affected by multiple parameters, including
tissue expression and processing and release by speciﬁc cells
into the circulation. Despite a lack of consensus on the
fraction of peripheral blood in which circulating miRNAs
should be measured, serum might be preferable in order toavoid a bias induced by leukocytes in whole blood samples.
First, as recently shown, circulating miRNA signatures may
be signiﬁcantly confounded by (disease-speciﬁc) over-
expression of hematopoietically derived miRNAs (31).
Second, inﬂammation-driven shifts in hematopoietic
compartments following MI, resulting in intraindividually
speciﬁc cell-subset kinetics and (stochastic) rapid ﬂuctuations
in leukocyte composition, would further impact the detection
of cell-free (truly circulating) miRNA species (32).
Given the lack of clearly deﬁned reference values with
cutoffs for the different miRNA concentrations, adequately
powered clinical studies are necessary to establish 75th, 90th,
97.5th, and 99th percentiles, as has been done with the
cardiac troponins (33,34).
Our study clearly shows that the release of muscle-
enriched, but not cardiac-speciﬁc, miRNAs (miR-1 and
miR-133a) occurred very early, within the ﬁrst minutes after
the induction of MI. We already detected the ﬁrst signiﬁ-
cant increases in miR-1 and miR-133a concentrations at the
ﬁrst post-induction time point of 15 min. The muscle-
enriched miRNAs were increased continuously during all
pre-speciﬁed time points within the ﬁrst 8 h. The concen-
trations of both miR-1 and miR-133a peaked between 75
Figure 2 Linear Regression Analysis of hs-cTnT and miRNAs in All Patients (N ¼ 21)
Logarithmic masses of (A) miR-1, (B) miR-133a, (C) miR-21, and (D) miR-208a during the ﬁrst 120 min after the induction of acute myocardial infarction.
hs-cTnT ¼ high-sensitivity cardiac troponin T; miR ¼ microRNA.
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highest concentrations of miR-1 and miR-133a at 156 min
after symptom onset in patients with STEMI, a ﬁnding that
supports our results.
There are inconsistent data concerning the detection of
circulating miR-208a concentrations in the setting of AMI.
Wang et al. (10) reported that cardiac-speciﬁc miR-208a is
elevated in the plasma of patients with AMI. De Rosa et al.
(12) showed profoundly elevated miR-208a concentrations
in patients with troponin-positive acute coronary syndromes
without a signiﬁcant transcoronary concentration gradient.
In contrast, D’Alessandra et al. (11) could not document any
increase in miR-208a in AMI patients. Consistently, the
concentration of miR-208a in the blood of healthy volun-
teers seems to be very low, which limits a precise quantitative
assessment (10–12). This study demonstrated that circu-
lating miR-208a concentrations are low compared with
those of miR-1 and miR-133a. miR-208a concentrations
were increased at 105 min after the induction of MI and
returned to baseline values after 24 h.
miR-21 is highly expressed in the heart and is up-
regulated in failing human hearts and in the presence ofcardiac hypertrophy (23–26). Published data have indi-
cated that cardiac hypertrophy–associated miRNAs are
also up-regulated in patients with AMI (15). Studies have
shown that circulating miR-21 concentrations are higher
in patients with AMI compared with those in patients
with acute heart failure and in healthy individuals (27,28).
This study showed a modest increase in miR-21 without
reaching statistical signiﬁcance in contrast to previously
published data demonstrating a considerable rise of this
miRNA in patients with AMI. This observation might be
explainable by higher in vitro and in vivo baseline
concentrations of miR-21 in cardiac hypertrophy without
the possibility of a further increase after initiated MI
(23–26).
The TASH model provides the unique opportunity to
compare the release kinetics of miRNAs with already
established biomarkers. The cardiac troponins are generally
acknowledged as the biochemical gold standard for the
detection of myocardial necrosis. We were recently able to
demonstrate a considerably early release of cTnT, measured
using a high-sensitivity assay, in comparison to other
myocardial biomarkers (19). A previous study identiﬁed
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997dysregulated miRNAs on admission in patients with
STEMI and hs-cTnT concentrations below 50 ng/l (15).
Therefore, the simultaneous increase of muscle-enriched
miR-1 and -133a after the induction of MI has an impor-
tant clinical implication as it seems to indicate myocardial
necrosis as early as does hs-cTnT. Understanding the time
frame of the increases in miRNA and the correlation with
a patient’s symptoms and electrocardiography and imaging
studies is necessary for developing their use as potential
biomarkers for MI. With the standardization of miRNA
measurements and the deﬁnition of reference values, circu-
lating miRNAs may be developed as biomarkers for AMI.
However, large-scale studies are necessary to validate the
superiority of one of the different miRNAs to cTnT or the
value of combining one with cTnT to improve the diag-
nostic accuracy in terms of a rapid rule-in and/or rule-out of
AMI.
Study limitations. This is the ﬁrst study of serial cardiac-
speciﬁc and muscle-enriched miRNA measurements in
patients with hypertrophic obstructive cardiomyopathy
undergoing TASH. However, the small number of enrolled
consecutive patients from a single center is a major limita-
tion that must be considered. The studied patients were
without coronary artery disease and therefore without the
possible phenomenon of ischemic pre-conditioning, which
may inﬂuence the release of ischemia-related miRNAs.
Furthermore, the kinetics of miRNA release after alcohol
ablation might be different from the release from the stut-
tering thrombotic occlusion of an epicardial coronary artery
where the vessel dynamically opens and closes during the
early period of AMI. Nonetheless, our data clearly dem-
onstrate a signiﬁcant increase in serum miR-1 and miR-
133a concentrations at the pre-speciﬁed time points.
Therefore, further measurements in clinical practice should
be initiated to establish the diagnostic sensitivity and
speciﬁcity of the miRNAs.Conclusions
Concentrations of muscle-enriched miR-1, miR-208a, and
miR-133a continuously rose during the ﬁrst 4 h after the
onset of MI. The ﬁrst signiﬁcant differences in miR-1 and
miR-133a concentrations compared with baseline occurred
at 15 min after the induction of MI. These results demon-
strate for the ﬁrst time the release kinetics of miRNAs,
which contribute to their potential development as cardiac
biomarkers.Acknowledgments
The authors are grateful to the Anna-Maria and Uwe
Karsten Kühl-Stiftung, Deutsches Stiftungszentrum, Essen,
Germany, and William G. Kerckhoff-Stiftung, Bad Nau-
heim, Germany, for research funding. The authors also
thank Dr. Alexander Berkovic, Kerckhoff Heart and ThoraxCenter, Bad Nauheim, Germany, for his advice regarding
statistical analysis.
Reprint requests and correspondence: Dr. Christoph Liebetrau,
Department of Cardiology, Kerckhoff Heart and Thorax Center,
Benekestrasse 2-8, 61231 Bad Nauheim, Germany. E-mail:
c.liebetrau@kerckhoff-klinik.de.REFERENCES
1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global
and regional burden of disease and risk factors, 2001: systematic
analysis of population health data. Lancet 2006;367:1747–57.
2. Kurz K, Giannitsis E, Becker M, Hess G, Zdunek D, Katus HA.
Comparison of the new high sensitive cardiac troponin T with
myoglobin, h-FABP and cTnT for early identiﬁcation of myocardial
necrosis in the acute coronary syndrome. Clin Res Cardiol 2011;100:
209–15.
3. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML,
Zeiher AM, CAPTURE Study Investigators. Pregnancy-associated
plasma protein-A levels in patients with acute coronary syndromes:
comparison with markers of systemic inﬂammation, platelet activation,
and myocardial necrosis. J Am Coll Cardiol 2005;45:229–37.
4. Khan SQ , Dhillon OS, Russel J, et al. C-terminal provasopressin
(Copeptin) as a novel and prognostic marker in acute myocardial
infarction. Leicester Acute Myocardial Infarction Peptide (LAMP)
study. Circulation 2007;115:2103–10.
5. Keller T, Zeller T, Peetz D, et al. Sensitive troponin i assay in early
diagnosis of acute myocardial infarction. N Engl J Med 2009;361:
868–77.
6. Weber M, Bazzino O, Estrada JLN, et al. Improved diagnostic and
prognostic performance of a new high sensitive troponin T assay in
patients with acute coronary syndrome. Am Heart J 2011;162:81–8.
7. Giannitsis E, Kehayova T, Vafaie M, Katus HA. Combined testing of
high sensitivity troponin T and copeptin on presentation at prespeciﬁed
cutoffs improves rapid rule-out of non–ST-segment elevation myo-
cardial infarction. Clin Chem 2011;57:1452–5.
8. Hamm CW, Bassand JP, Agewall S, et al., European Society of
Cardiology (ESC) Task Force for the Management of Acute Coronary
Syndromes (ACS) in Patients Presenting Without Persistent ST-
Segment Elevation. ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent ST-
segment elevation. Eur Heart J 2011;32:2999–3054.
9. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in
patients with coronary artery disease. Circ Res 2010;107:677–84.
10. Wang GK, Zhu JQ , Zhang JT, et al. Circulating microRNA: a novel
potential biomarker for early diagnosis of acute myocardial infarction in
humans. Eur Heart J 2010;31:659–66.
11. D’Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs
are new and sensitive biomarkers of myocardial infarction. Eur Heart J
2010;31:2765–73.
12. De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S,
Zeiher AM. Transcoronary concentration gradients of circulating
microRNAs. Circulation 2011;124:1936–44.
13. Eitel I, Adams V, Dieterich P, et al. Relation of circulating microRNA-
133a concentrations with myocardial damage and clinical prognosis in
ST-elevation myocardial infarction. Am Heart J 2012;164:706–14.
14. LongG,WangF,DuanQ , et al. CirculatingmiR–30a,miR–195 and let–
7b associated with acute myocardial infarction. PLoSOne 2012;7:e50926.
15. Vogel B, Keller A, Frese K, et al. Reﬁning diagnostic microRNA
signatures by whole-miRNome kinetic analysis in acute myocardial
infarction. Clin Chem 2013;59:410–8.
16. Duan X, JiB Wang X, et al. Expression of microRNA-1 and
microRNA-21 in different protocols of ischemic conditioning in an
isolated rat heart model. Cardiology 2012;122:36–43.
17. Clements P, Brady S, York M, et al. Time course characterization of
serum cardiac troponins, heart fatty acid–binding protein, and
morphologic ﬁndings with isoproterenol-induced myocardial injury in
the rat. Toxicol Pathol 2010;38:703–14.
Liebetrau et al. JACC Vol. 62, No. 11, 2013
Release Kinetics of MicroRNAs September 10, 2013:992–8
99818. Smithline HA, Thompson M, Moran C, Mader TJ. Can CK-MB and
cTn-I be detected in the peripheral circulation within the ﬁrst 10 min
of acute coronary ischemia? Med Hypotheses 2003;60:598–602.
19. Liebetrau C, Moellmann H, Nef H, et al. Release kinetics of cardiac
biomarkers in patients undergoing transcoronary ablation of septal
hypertrophy. Clin Chem 2012;58:1049–54.
20. Liebetrau C, Nef H, Szardien S, et al. Release kinetics of copeptin in
patients undergoing transcoronary ablation of septal hypertrophy. Clin
Chem 2013;59:566–9.
21. Maron BJ, McKenna WJ, Danielson GK, et al., for the Task Force on
Clinical Expert Consensus Documents, American College of Cardi-
ology, Committee for Practice Guidelines; European Society of
Cardiology. American College of Cardiology/European Society of
Cardiology clinical expert consensus document on hypertrophic
cardiomyopathy. A report of the American College of Cardiology
Foundation Task Force on Clinical Expert Consensus Documents and
the European Society of Cardiology Committee for Practice Guide-
lines. J Am Coll Cardiol 2003;42:1687–713.
22. Long G, Wang F, Duan Q , et al. Human circulating microRNA-1
and microRNA-126 as potential novel indicators for acute myocardial
infarction. Int J Biol Sci 2012;8:811–8.
23. Kumarswamy R, Volkmann I, Thum T. Regulation and function of
miRNA-21 in health and disease. RNA Biol 2011;8:706–13.
24. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease.
J Cardiovasc Transl Res 2010;3:251–5.
25. Matkovich SJ, Van Booven DJ, Youker KA, et al. Reciprocal regulation
of myocardial microRNAs and messenger RNA in human cardiomy-
opathy and reversal of the microRNA signature by biomechanical
support. Circulation 2009;119:1263–71.
26. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in
hypertrophic heart: do they play a role in cardiac hypertrophy? Am J
Pathol 2007;170:1831–40.27. Corsten MF, Dennert R, Jochem S, et al. Circulating microRNA-208b
and microRNA-499 reﬂect myocardial damage in cardiovascular
disease. Circ Cardiovasc Genet 2010;3:499–506.
28. Olivieri F, Antonicelli R, Lorenzi M, et al. Diagnostic potential of
circulating miR-499-5p in elderly patients with acute non ST-elevation
myocardial infarction. Int J Cardiol 2013;167:531–6.
29. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic
impact of six circulating microRNAs in acute coronary syndromes.
J Mol Cell Cardiol 2011;51:872–5.
30. Salic K, De Windt LJ. MicroRNAs as biomarkers for myocardial
infarction. Curr Atheroscler Rep 2012;14:193–200.
31. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of
cellular miRNAs on circulating biomarker signatures. PLoS One 2011;
6:e20769.
32. Hoffmann J, Fiser K, Weaver J, et al. High-throughput 13-parameter
immunophenotyping identiﬁes shifts in the circulating T-cell com-
partment following reperfusion in patients with acute myocardial
infarction. PLoS One 2012;7:e47155.
33. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR,
White HD, the Writing Group on behalf of the Joint ESC/ACCF/
AHA/WHF Task Force for the Universal Deﬁnition of Myocardial
Infarction. Third universal deﬁnition of myocardial infarction. J Am
Coll Cardiol 2012;60:1581–98.
34. Eggers KM, Jaffe AS, Lind L, Venge P, Lindahl B. Value of cardiac
troponin I cutoff concentrations below the 99th percentile for clinical
decision-making. Clin Chem 2009;55:85–92.Key Words: acute myocardial infarction - muscle-enriched
microRNAs - release kinetics - transcoronary ablation of septal
hypertrophy.
